Attenuation of experimental autoimmune demyelination in complement-deficient mice

Journal of Immunology

Volumn 165, Issue 10, 2000, Pages 5867-5873

  Nataf, S ^a   Carroll, S L ^a   Wetsel, R A ^a   Szalai, A J ^a   Barnum, S R ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; COMPLEMENT MEMBRANE ATTACK COMPLEX;

ALLERGIC ENCEPHALITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT DEFICIENCY; CONTROLLED STUDY; DEMYELINATION; FEMALE; INFLAMMATORY CELL; INFLAMMATORY DISEASE; MACROPHAGE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0034669915     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.10.5867     Document Type: Article

References (51)

1. The immunogenesis of the multiple sclerosis plaque
2. Immunofluorescence study of brain plaques from two patients with multiple sclerosis
3. Immunocytochemical localization of the terminal complement complex in multiple sclerosis
4. Multiple sclerosis: In situ evidence for antibody- and complement-mediated demyelination
5. Identification of autoantibodies associated with myelin damage in multiple sclerosis
6. Enhanced expression of chemotactic receptors in multiple sclerosis lesions
7. Kinetics of anaphylatoxin C5a receptor expression during experimental allergic encephalomyelitis
8. Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells
9. TNF-α suppresses CR3-mediated myelin removal by macrophages
10. Macrophage phagocytosis of myelin in vitro determined by flow cytometry: Phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-α and nitric oxide
11. Terminal complement complexes induce cell cycle entry in oligodendrocytes through mitogen activated protein kinase pathway
12. Sublytic complement attack induces cell cycle in oligodendrocytes
13. Allergic encephalomyelitis: Effect of complement depletion with cobra venom
14. Prevention of experimental allergic encephalomyelitis with cobra venom factor
15. Experimental allergic encephalomyelitis in cobra venom factor-treated and C4-deficient guinea pigs
16. The role of complement in the pathogenesis of experimental allergic encephalomyelitis
17. Antibody-mediated demyelination in experimental allergic encephalomyelitis is independent of complement membrane attack complex formation
18. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis
19. Experimental allergic encephalomyelitis in the absence of a classical delayed-type hypersensitivity reaction: Severe paralytic disease correlates with the presence of interleukin 2 receptor-positive cells infiltrating the central nervous system
20. Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis
21. B-cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization
22. B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by short encephalitogenic peptide
23. Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA
24. Abrogation of the alternative complement pathway by targeted deletion of murine factor B
25. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination
26. Solid phase enzyme immunoassays for the quantification of serum amyloid P (SAP) and complement component 3 (C3) proteins in acute-phase mouse sera
27. Myelin oligodendrocyte glycoprotein: A novel candidate autoantigen in multiple sclerosis
28. The role of complement and complement receptors in induction and regulation of immunity
29. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B
30. 14C-labeled cells during acute, chronic, and relapsing experimental allergic encephalomyelitis
31. Enhanced T cell migration to sites of microscopic CNS disease: Complementary treatments evaluated by 2- and 3-D image analysis
32. Human T cells express the C5a receptor and are chemoattracted to C5a
33. In vitro and in vivo dependency of chemokine generation on C5a and TNF-α
34. 2+](i) signaling in mouse microglia
35. Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease
36. Mechanisms of enhanced lung injury during sepsis
37. Synergistic enhancement of chemokine generation and lung injury by C5a or the membrane attack complex of complement
38. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity
39. Leukocyte entry into sites of inflammation requires overlapping interactions between the L-selectin and ICAM-1 pathways
40. Type 1 astrocytes and oligodendrocyte-type 2 astrocyte glial progenitors migrate toward distinct molecules
41. Chemotaxis by a CNS macrophage, the microglia
42. Complement C5a controls motility of murine microglial cells in vitro via activation of an inhibitory G-protein and the rearrangement of the actin cytoskeleton
43. Experimental allergic encephalomyelitis is delayed and attenuated in C5aR KO mice
44. Complement depletion reduces macrophage infiltration and activation during Wallerian degeneration and axonal regeneration
45. Treatment with anti-CR3 antibodies ED7 and ED8 suppresses experimental allergic encephalomyelitis in Lewis rats
46. Macrophage phagocytosis of myelin in vitro determined by flow cytometry: Phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-α and nitric oxide
47. Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit
48. Complement-independent activation of the fifth component (C5) of human complement: Limited trypsin digestion resulting in the expression of biological activity
49. Expression of C5a-like biological activities by the fifth component of human complement (C5) upon limited digestion with noncomplement enzymes without release of polypeptide fragments
50. CNS-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis
51. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor